Yesterday's BIOrdle ticker was APVO. Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology developing immuno-oncology therapeutics. Aptevo has a catalyst planned for mid-2022 for its Phase 1b trial of APVO436 to treat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Shares closed yesterday up 6% at $3.70.
__________________________
Athira Pharma, Inc. (NASDAQ: ATHA) announced topline results from its Phase 2 ACT-AD trial of fosgonimeton (ATH-1017) to treat mild-to-moderate Alzheimer's disease (AD). The trial did not meet its primary endpoint of change in biomarker ERP P300 latency.
Codex DNA (NASDAQ: DNAY) shares are trading up during the premarket following an SEC form 4 from Codex COO Esser Eric Eugene was filed on June 15, 2022. The COO acquired 225 thousand stock options at $2.71 per share price.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced two changes to its cash runaway guidance after it entered into a collaboration and license agreement with Novartis Pharma AG (NYSE: NVS) for $75 million upfront and up to $1.4 billion in milestone to develop a in vivo gene therapy treatment for sickle cell disease and beta thalassemia. Precision also announced an offering of 35,971,224 shares at $1.39 per share for gross proceeds of approximately $50 million.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) announced top line results of its Phase 2 INSPIRE trial of Zygel to treat symptoms of 22q11.2 deletion syndrome. The trial met multiple efficacy assessments, and Zynerba is planning a meeting with the FDA to discuss the next steps in development.
Rockwell Medical Inc (NASDAQ: RMTI) announced the appointment of Mark Strobeck as President And Chief Executive Officer, effective July 1, 2022.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) released data from the first two patients from its Phase 1/2 clinical trial of BBP-812 to treat Canavan disease. Initial pharmacodynamic results noted decreases in N-acetylaspartate (NAA) in the brain and urine.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced that the FDA approved its Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets, a generic version of the Reference Listed Drug (RLD) Tranxene.